In response to the rapidly rising intravenous opioid abuse epidemic, the United States Food and Drug Administration is currently promoting the development of prescription opioid tablets that are specifically formulated to deter abuse. Opana ER® (Endo Pharmaceuticals) recently underwent reformulation to include a crush-resistant coating. Only recently described, illicit intravenous injection of reformulated Opana ER® is associated with a distinctive clinical syndrome of thrombotic microangiopathy.
- Expression Profile of Hepatic Metallothionein-I and ATP7B, and Brain Metallothionein-III and Acetyl cholinesterase Genes in Wistar Rat Model for Non-Wilsonian Brain Copper Toxicosis
- Retained Mesoappendix Fat Nodule Mimicking Appendicitis
- Meningoencephalitis due to Enteroviral Infection – An Often Overlooked Etiology
- Non-ARV Prescriptions and Medication Burden among Commercially Insured U.S. HIV Patients
- Dermatophytosis in a Dog Seropositive for Ehrlichia Spp
- Adults Mammary Stem Cell in Cow’s Milk: New Perspectives and Future Challenge
- Wake-up Strokes Are Similar to Known-Onset Morning Strokes in Severity and Outcome
- Improvement in Latent Fingermark Detection on Thermal Paper using 5,6-Dimethoxy-1,2-indandione/PVP
- Milk Drinking Patterns among Malaysian Urban Children of Different Household Income Status
- Effects of Pioglitazone on the Electrocardiogram in the Goto-Kakizaki Type 2 Diabetic Rat Heart
Annex PublishersAnnex Publishers, as an Open Access publication model allows the dissemination of research articles to the worldwide community. We offer you the advantage of interaction with the most effective minds from the scientific community. All articles printed under open access will be accessed by anyone.
Provides for unrestricted access to journals and publications, along with an ideal platform for thousands of scholarly brains to return together for development of science. Open Access helps accelerate the pace of scientific discovery, encourage innovation, enrich education, and stimulate the economy to enhance the knowledge of the general public.
A monoclonal antibody (Mab) designated as GHR106 was generated against the extracellular domain (N1-29 synthetic peptide) of human gonadotropin releasing hormone (GnRH) receptor. It is a first-in-class GnRH analog and can serve as a drug candidate for potential applications in the treatment of human cancers and/or fertility regulations.
They are cytokines secreted by adipose tissue considered to be immunomodulating agents, however they can be more accurately put into the larger, growing list of adipose-derived hormones.
The Effect of Interleukin-6-Type Cytokines and Adiponectin on MAPK Activation in the Immortalized Human Chondrocyte C28/I2 Line and Normal Human Chondrocytes
The C28/I2 line of immortalized juvenile human chondrocytes was employed to determine the extent to which recombinant human (rh) interleukin-6 (rhIL-6), the interleukin-6-like cytokine, rh-oncostatin M, and the adipokine, rh-adiponectin, activated extracellularsignal regulated kinase (ERK1/2), p38α mitogen-activated protein kinase (p38α MAPK) and c-Jun-amino-terminal kinase (JNK).